Qpex Biopharma Names New President

Qpex Biopharma Inc., a Shionogi Group Company, has appointed Gareth Morgan, MS, MBA, most recently SVP and Global Head of Portfolio Management and AMR Policy at Shionogi Inc., as President of Qpex.

Morgan succeeds Michael Dudley, Pharm.D., who has retired and stepped down from his role as President and CEO. Dudley will continue to serve as a strategic advisor to Qpex and Shionogi.

About Gareth Morgan

Prior to joining Shionogi in 2007, Morgan held clinical development and project management roles at large pharmaceutical companies, where he oversaw teams focusing on global and domestic registrational studies across multiple therapeutic areas.

During his tenure at Shionogi, Morgan has been instrumental in the company’s global siderophore cephalosporin discovery program. He has led efforts to establish several important public-private partnerships and led the establishment of a landmark license and technology transfer agreement with the Global Antibiotic Research and Development Partnership (GARDP) and a collaboration agreement with the Clinton Health Access Initiative (CHAI) that aim to transform access to antibiotics in low- and middle-income countries.